Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
Lillegraven S, Paulshus Sundlisæter N, Aga AB, Sexton J, Olsen IC, Lexberg ÅS, Madland TM, Fremstad H, Høili CA, Bakland G, Spada C, Haukeland H, Hansen IM, Moholt E, Uhlig T, Solomon DH, van der Heijde D, Kvien TK, Haavardsholm EA. Lillegraven S, et al. Among authors: paulshus sundlisaeter n. Ann Rheum Dis. 2023 Nov;82(11):1394-1403. doi: 10.1136/ard-2023-224476. Epub 2023 Aug 22. Ann Rheum Dis. 2023. PMID: 37607809 Free PMC article. Clinical Trial.
Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes.
Paulshus Sundlisæter N, Aga AB, Olsen IC, Hammer HB, Uhlig T, van der Heijde D, Kvien TK, Lillegraven S, Haavardsholm EA; ARCTIC study group. Paulshus Sundlisæter N, et al. Ann Rheum Dis. 2018 Oct;77(10):1421-1425. doi: 10.1136/annrheumdis-2017-212830. Epub 2018 Jun 22. Ann Rheum Dis. 2018. PMID: 29934373
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
Lillegraven S, Paulshus Sundlisæter N, Aga AB, Sexton J, Olsen IC, Fremstad H, Spada C, Madland TM, Høili CA, Bakland G, Lexberg Å, Hansen IJW, Hansen IM, Haukeland H, Ljoså MA, Moholt E, Uhlig T, Solomon DH, van der Heijde D, Kvien TK, Haavardsholm EA. Lillegraven S, et al. Among authors: paulshus sundlisaeter n. JAMA. 2021 May 4;325(17):1755-1764. doi: 10.1001/jama.2021.4542. JAMA. 2021. PMID: 33944875 Free PMC article. Clinical Trial.
Subclinical inflammation and joint damage progression in patients with early RA fulfilling 2011 vs 2022 ACR/EULAR Boolean remission criteria: data from the ARCTIC study.
Melokhina V, Paulshus Sundlisæter N, Sexton J, Sundin U, Aga AB, Kjørholt KE, Nordberg LB, van der Heijde D, Haavardsholm E, Lillegraven S. Melokhina V, et al. Among authors: paulshus sundlisaeter n. Ann Rheum Dis. 2024 Mar 12;83(4):540-541. doi: 10.1136/ard-2023-224950. Ann Rheum Dis. 2024. PMID: 38049997 No abstract available.
Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity.
Holten K, Paulshus Sundlisæter N, Sexton J, Nordberg LB, Uhlig T, Kvien TK, Solomon DH, Haavardsholm EA, Lillegraven S, Aga AB; ARCTIC REWIND study group. Holten K, et al. Among authors: paulshus sundlisaeter n. RMD Open. 2024 Jan 12;10(1):e003486. doi: 10.1136/rmdopen-2023-003486. RMD Open. 2024. PMID: 38216290 Free PMC article. Clinical Trial.